We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Safety Concerns Could Trip Up AZ’s Gout Candidate Lesinurad
Safety Concerns Could Trip Up AZ’s Gout Candidate Lesinurad
FDA reviewers are questioning the safety and dosing of AztraZeneca’s investigational gout treatment lesinurad and whether a risk evaluation and mitigation strategy would suffice to address those concerns.